Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-Hodgkin's Lymphoma Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage II Nodal Marginal Zone Lymphoma Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage III Nodal Marginal Zone Lymphoma Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Ann Arbor Stage IV Follicular Lymphoma Ann Arbor Stage IV Nodal Marginal Zone Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Indolent Non-hodgkin Lymphoma Stage II Splenic Marginal Zone Lymphoma Stage III Splenic Marginal Zone Lymphoma Stage IV Splenic Marginal Zone Lymphoma • Previously untreated, histologically confirmed indolent non-Hodgkin's lymphoma as follows Follicular lymphoma (World Health Organization [WHO] classification grade 1, 2, or 3a) Marginal zone lymphoma including Nodal and splenic marginal zone lymphoma (MZL) who have an indication for systemic therapy Extranodal MZL Nongastric/noncutaneous MZL requiring systemic therapy Cutaneous MZL will be eligible only if they have pathologically confirmed extra-cutaneous disease Gastric MZL only if stage IIIE/IV defined as lymph node involvement on both sides of the diaphragm or with disseminated extranodal disease such as bone marrow or additional extra nodal sites Pathological diagnosis should be obtained by incisional or excisional tissue biopsy; core biopsy is permissible if obtaining an incisional or excisional is not possible and if the grade can be assessed on the core biopsy. A core biopsy can also be used if deemed in the best interest of the patient in the opinion of the investigator Patients must have stage II-IV disease  Prior history of malignancies unless the patient has been disease free for >= 5 years; exceptions basal cell carcinoma or squamous cell carcinoma of the skin; carcinoma in situ of cervix; carcinoma in situ of breast, localized prostate cancer, or superficial bladder cancer that has undergone curative therapy Prior therapy for lymphoma including chemotherapy or immunotherapy including ibrutinib/anti-CD20 agents; patient may have received corticosteroids, but should be off them 2 weeks prior to study entry; known prior significant hypersensitivity to obinutuzumab (not including infusion reactions) or ibrutinib Patients with evidence of large B cell transformation (transformed disease) are not eligible Known central nervous system (CNS) involvement by lymphoma Known bleeding disorders (e.g., von Willebrand's disease or hemophilia) Concomitant use of warfarin or other vitamin K antagonists Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of cycle 1 Known infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1) seropositive status Viral hepatitis